RxDoctor Payments Data

Satish Arora, MD

Ophthalmology · Thibodaux, LANPI 1700827805

Payments from drug & device makers

$714in general payments, 2019–2025

Across 26 payments — averaging $27.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$256
  • Apellis Pharmaceuticals, Inc.$182
  • AbbVie$69
  • Astellas Pharma US Inc$47
  • Novartis$46
  • Coherus Oncology, Inc.$23
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$69497%
  • Gifts$193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$714 in reported general payments places this provider in the 30th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,558,610
Medicare patients
952
Services billed
12,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine37$22,361
IlevroNepafenac44$20,265
Brimonidine Tartrate245$20,202
Alphagan PBrimonidine Tartrate45$16,562
Prednisolone Acetate216$8,548
Restasis MultidoseCyclosporine11$6,928
Latanoprost315$3,123
Travoprost21$2,692
Ketorolac Tromethamine95$2,567
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$1,887
Timolol Maleate175$1,643
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat150$1,483
ValacyclovirValacyclovir Hcl18$1,330
Ofloxacin113$1,312
Dorzolamide Hcl58$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Restasis Multidose$69$45,85093 claims
NovartisIlevro$46$20,26544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →